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Updated Recommendations
for Cost-effectiveness Studies
To theEditorCost-effectiveness isa relativelynewdiscipline, for
whichguidelinescontinue tobedevelopedandrefined.Thear-
ticle by Dr Sanders and colleagues1 offered updated reference
casesandperspectivesaswell asachecklist inanattempt to im-
prove standards andminimize bias in published studies.
There is evidence that cost-effectiveness studies spon-
sored by pharmaceutical companies aremore likely to report
positive cost-effective results.2 As ameans to address this and
other potential biases,we agreewith the authors’ recommen-
dations to require a true societal health care perspective and
include an impact inventory.
The authors included in the checklist that an analytic
plan be described within the article. We propose that not only
should the analytic plan be described in the methods section,
but it should also be made public prior to the analysis. This
would hold cost-effectiveness studies to the same standards
as systematic reviews and randomized clinical trials, both of
which have guidelines that require registration of studies
that detail the methods and outcomes prior to execution.3,4
Registration of systematic reviews and randomized clinical
trials have been incorporated into guidelines in an effort to
address the problems of multiple comparisons and selective
outcomes reporting.
Requiring cost-effectiveness investigators to commit to a
prespecified analytic plan would promote transparency and
differentiation between a priori and post hoc analyses. This
differentiation would encourage investigators to develop
robust analytic plans prior to performing their analysis and
would limit the risk of manipulation of the model until the
desired result is obtained, a problem similar to that found in
multiple comparisons. The additional transparency would
allow readers to understand more thoroughly how the inves-
tigators arrived at their results and see what modifications
they made along the way.
Cost-effectiveness methodology has developed signifi-
cantly during the last fewdecades and these new recommen-
dations shouldhelp advance it even further. Anadded recom-
mendation of trial registration would be another means of
guarding against bias in a field just coming of age.
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To the Editor Dr Sanders and colleagues1 updated the guide-
lines for the reporting and conduct of cost-effectiveness stud-
ies. Theirmain recommendation for the inclusion of findings
based on a societal perspective alongside the conventional
health sector perspectivewill enable these types of studies to
reflect thewider social benefits of improving health, particu-
larly of interventions that primarily target health systems and
populations rather than individuals.2
In operationalizing a societal perspective, Sanders and
colleagues1 recommended the reporting of an impact inven-
tory, which is an extensive list of outcomes attributed to the
intervention including nonhealth as well as health indica-
tors. Such lists are generally produced as part of a cost-
consequence analysis and are not new.3 Although impact in-
ventories areprone to the selective reportingof outcomes, the
newguidelines guardagainst this by recommendingprespeci-
fied economic evaluation protocols.
Nevertheless, the guidelines could be strengthened by
also requiring the presentation of a predefined theoretical
framework in each study that should indicate why thesemul-
tiple outcomes are expected to be influenced by the interven-
tion. This would act as a validity check on the composition of
the impact inventories by making explicit proposed mecha-
nisms of action and their link to the items listed in the inven-
tories. The evaluation of a trial investigating a microfinance
and health education intervention (primarily designed to
prevent gender violence and spread of human immunodefi-
ciency virus infection in rural communities in South Africa)
provides an example of how such frameworks could be
presented.4
In that study,4 outcomeswere prespecified at individual,
household,andcommunity levelsandheldtogetherbyanover-
arching theoretical framework, indicating how the behaviors
influenced by the intervention were linked to outcomes via
multiple pathways. Prespecifying outcomes through this
framework provided a comprehensive, multileveled account
ofhowthe interventioneventuallyeffectedchange in thecom-
munity and thus enabled a rigorous assessment of the social
effect of the program.5
The update of the guidelines on the reporting of cost-
effectiveness studies will help to generate the broad-ranging
evidence needed to account for a societal perspective in the
economic evaluation of health programs. The augmentation
of these changes with the requirement to prespecify a theo-
retical framework justifying the outcomes assessed in each
study will ultimately strengthen the credibility and utility of
this evidence.
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In Reply We agree that both prespecification of cost-
effectiveness analysis protocols and a common frame-
work for summarizing the impact inventory would increase
transparency, reduce the risk of bias, and promote the devel-
opment anddissemination of high-quality cost-effectiveness
analyses.
In the article and the book,1 the Second Panel on Cost-
Effectiveness in Health and Medicine recommended that a
written protocol be developed at the outset of an analysis
that details key aspects of the study’s design and conduct
(eg, the objective; the intervention, comparators, and popu-
lations under consideration; the time horizon; sources of
data; key assumptions) and that this protocol be updated,
and changes noted as the study progresses.
Thepanel discussedwhether to recommend that thepro-
tocolbemadepubliclyavailableat theoutsetof thestudy, simi-
lar to the requirements for systematic reviews and random-
ized clinical trials. The panel was supportive of such a
requirement but viewed the question of how best to develop
the needed infrastructure as a topic for future research.
A general framework describing the mechanisms of ac-
tion of interventions, and their links to the items in the im-
pact inventory,would also increase the comparability and the
effect of cost-effectiveness analyses. Development of such a
framework,which corresponds to the structure of the impact
inventory and suits most analyses, is an important future re-
search need.
In the meantime, the panel’s recommendation 3C ad-
vises analysts to present both summary and disaggregated
measures of costs andhealth outcomes but stops short of rec-
ommending a single summarymeasure. Analysts can decide
which items in the impact inventory to include in 1 or more
summary measures and should clearly identify which items
are included,describehowtheyaremeasuredandvalued, and
provide a rationale for their inclusion.
Westrongly support explorationof these topics as the field
moves forward.
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CORRECTION
Omission of Funding/Support and Role of the Sponsor Acknowledgments
andDisclaimer: In theOriginal Investigation entitled “Association Between End-
of-Rotation Resident Transition in Care and Mortality Among Hospitalized Pa-
tients” published in the December 6, 2016, issue of JAMA,1 a funding/support ac-
knowledgment and disclaimer were inadvertently omitted. A Funding/Support
section should read: “Thismaterial is the result ofwork supportedwith resources
and the use of facilities at the Veterans Affairs New York Harbor Healthcare Sys-
tem.” A Role of the Sponsor section should read: “The Veterans Affairs New York
HarborHealthcare Systemhadno role in thedesign andconduct of the study; col-
lection, management, analysis, and interpretation of the data; preparation, re-
view,orapprovalof themanuscript; anddecision tosubmit themanuscript forpub-
lication.”Also,aDisclaimershouldread: “Theviewsexpressed inthisarticlearethose
of the authors and do not necessarily reflect the position or policy of the Depart-
ment of Veterans Affairs or the United States government.” This article was cor-
rected online.
1. Denson JL, Jensen A, Saag HS, et al. Association between end-of-rotation
resident transition in care andmortality among hospitalized patients. JAMA.
2016;316(21):2204-2213.
Missing Negative Symbol: In the Special Communication entitled “The Associa-
tion Between Income and Life Expectancy in the United States, 2001-2014” pub-
lished in the April 26, 2016, issue of JAMA,1 a negative symbol wasmissing from a
95%CI that appeared in Figure 8. In Figure 8, “Index for preventive care” row, the
Pearson correlation coefficient (95%CI) data in column 2 should be “0.05 (−0.19
to0.29).” In the online Supplement, an incomplete formula and 2 errors in eTable
1B have been corrected. This article was corrected online.
1. Chetty R, Stepner M, Abraham S, et al. The association between income and
life expectancy in the United States, 2001-2014. JAMA. 2016;315(16):1750-1766.
LanguageChange: TheViewpoint entitled “What toBelieveandDoAboutStatin-
Associated Adverse Effects”1 published in the November 15, 2016, issue of JAMA,
included an inaccurate sentence regarding the findings of the STOMP trial. It was
corrected to read: “This finding did not reach statistical significance, but patients
takingstatinsdevelopedsymptomsatapproximately twice the rateofpatients tak-
ing placebo.” This article was corrected online.
1. Thompson PD.What to believe and do about statin-associated adverse
effects. JAMA. 2016;316(19):1969-1970.
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